The treatment is generally well-tolerated under medical supervision, though some individuals may experience mild, transient gastrointestinal effects as the body adapts
GLP-1 is produced primarily by specialized cells, called L-cells, in the lining of your small intestine
To summarize the last article: GLP-1 medications are reshaping modern medicine because they target the gut-brain-metabolic axis that drives most chronic disease - not just weight loss, but cardiovascular disease, heart failure, kidney disease, neurodegeneration, fatty liver, and systemic inflammation
Retatrutide represents the next generation of weight loss medications, developed by Eli Lilly as a once-weekly injectable peptide that targets three distinct metabolic pathways simultaneously